Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation.

Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.

Key Stats

• Today's Range: $1.34 to $1.40
• 50-Day Range: $1.20 to $1.82
• 52-Week Range: $1.20 to $6.18
• Volume: 40,758 shs
• Average Volume: 96,697 shs
• Market Capitalization: $4.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scinai Immunotherapeutics Stock Analysis - MarketRank™

Scinai Immunotherapeutics scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Scinai Immunotherapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scinai Immunotherapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scinai Immunotherapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scinai Immunotherapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.83% of the outstanding shares of Scinai Immunotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently decreased by 16.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scinai Immunotherapeutics does not currently pay a dividend.

Dividend Growth

Scinai Immunotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.83% of the outstanding shares of Scinai Immunotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently decreased by 16.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.95

News Sentiment

Scinai Immunotherapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Scinai Immunotherapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCNI Stock Analysis - Frequently Asked Questions

How have SCNI shares performed this year?

Scinai Immunotherapeutics' stock was trading at $3.35 at the beginning of the year. Since then, SCNI stock has decreased by 58.8% and is now trading at $1.38.

How were Scinai Immunotherapeutics' earnings last quarter?

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) posted its quarterly earnings results on Wednesday, May, 7th. The company reported ($10.40) earnings per share for the quarter. The firm had revenue of $0.21 million for the quarter.

When did Scinai Immunotherapeutics' stock split?

Scinai Immunotherapeutics shares reverse split on the morning of Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Scinai Immunotherapeutics?

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scinai Immunotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 0.71
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $660 thousand
• Price / Sales: 6.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.10 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 3,190,000
• Free Float: 2,996,000
• Market Cap: $4.40 million
• Optionable: Not Optionable
• Beta: 1.90